This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing! Wegovy is the weight-loss application for the drug Samglutide (Ozempic is the Type 2 Diabetes application of the same drug) which is owned by Novo Nordisk.
I happened to be looking at side effects re: GLP1s. I found that Drug Watch lists them as high risk drugs and indicates that there are open class action lawsuits for
Thank you for this, as always! Please please please also dig into the heart failure study. This is exactly my condition and I assume it’s the same situation as this blitz! https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
There maybe an obvious answer to this. I am wondering how these researchers get paid otherwise for their work? And how do they get the work? Who regularly employs them?
I think you mean 8% for the placebo group (not 8.5%)? "Per the study, 6.5% of patients who took semaglutide experienced death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke while 8.5% of the group taking the placebo did." Thank you for all this digging, synthesising, and analysis!
Thank you so much for doing this!
I appreciate both your efforts and your integrity
I happened to be looking at side effects re: GLP1s. I found that Drug Watch lists them as high risk drugs and indicates that there are open class action lawsuits for
Ozempic (semaglutide) at https://www.drugwatch.com/drugs/ozempic/side-effects/
and
Mounjaro (tirzepatide) https://www.drugwatch.com/drugs/mounjaro/side-effects/
Thank you for this, as always! Please please please also dig into the heart failure study. This is exactly my condition and I assume it’s the same situation as this blitz! https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
There maybe an obvious answer to this. I am wondering how these researchers get paid otherwise for their work? And how do they get the work? Who regularly employs them?
Thanks Ragan!
I think you mean 8% for the placebo group (not 8.5%)? "Per the study, 6.5% of patients who took semaglutide experienced death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke while 8.5% of the group taking the placebo did." Thank you for all this digging, synthesising, and analysis!
Wow. There is no such thing as tenets of medical ethics anymore. I share some of your links on the shownotes of this podcast.
Dr. Mark Cucuzzella on the Latest GLP-1 Weight-Loss Medications! 600
https://www.myboundlessbody.com/podcast-1/episode/7bead7e7/dr-mark-cucuzzella-on-the-latest-glp-1-weight-loss-medications-600